antibodies developer News
-
Neutralizing Antibody Development for SARS-CoV-2 Available at Creative Biolabs
The continuous spread of COVID-19 has become a threat to global health and even has led to a global economic crisis. Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs. Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, ...
-
CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development
Prominent within the field of computational biology, CD ComputaBio, unveils its cutting-edge Antibody Drug Design Services and Antibody Development solutions. Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, fostering innovation within the healthcare industry. In ...
-
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
VANCOUVER, British Columbia, – AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government to supply up to 600,000 doses, for at least $720 million, of investigational drug bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Lilly. The U.S. government will accept the ...
-
Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old ...
By Synaffix BV
-
IntoCell and Ab Studio to Start Research Collaboration
IntoCell, a South Korean biotech developing novel antibody drug conjugate (ADC) platform technologies, today announced the signing of a research collaboration with Ab Studio, a US biotech focused on the discovery of novel antibodies. The collaboration will include construction of a panel of ADCs by integrating IntoCell's proprietary payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) ...
-
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data Previously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concern Bebtelovimab binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting the potential to ...
-
Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022
Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company was awarded ‘Best ADC Platform Technology’ at the World ADC Conference 2022. This marks the second time that Synaffix’ groundbreaking ADC platform ...
By Synaffix BV
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
-
Engineering antibody-antigen interfaces to improve therapeutic properties
Antibodies (immunoglobulins) are a key component of the mammalian immune response and are increasingly of interest as a means of therapy for several diseases. In fact, there are over 100 monoclonal antibodies that have been approved as drugs1. Despite this apparent success, there are issues with biopharmaceutical antibody research and development – not least the cost of goods. Although it ...
-
Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease
Biolojic Design (“Biolojic”), a biotechnology company that computationally designs functional antibodies, today announced that it has entered into a research collaboration and license option agreement with Nektar Therapeutics to discover and develop agonistic antibodies that activate a novel and previously un-drugged target for the treatment of autoimmune disease. Financial terms of ...
-
Creative Biolabs Upgrades Proteomics Technologies for Exosomal Cargo and Biomarker Research
Exosomes, small lipid bilayer-enclosed particles of endosomal origin, are a subset of extracellular vesicles (EVs) that are secreted by most cell types. They are spherical, bilayered proteolipids and show a diverse mixture of exosomal nucleic acids (mRNA and non-coding RNA), proteins, and lipids, among which exosomal proteins play a key role in the pathological process of various diseases. At ...
-
Synaffix Licenses CliCr Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
Synaffix obtains exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology CliCr® further expands the repertoire of payloads suitable for conjugation by enhancing reactivity, stability and hydrophilicity Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of ...
By Synaffix BV
-
Genmab and Synaffix Enter into $415m License Agreement for ADC Technology
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single ...
By Synaffix BV
-
Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E-Based ADCs
Winning scientific poster shows complete tumor regression and high tolerability of SYNtecan E™ based ADCs SYNtecan E™ linker-payload is developed by Synaffix based on the potent DNA topoisomerase 1 inhibiting exatecan Additionally, Synaffix was awarded ‘Runner-Up’ for the 2021 Best ADC Platform Technology (Winner in 2020) Synaffix B.V., a biotechnology company ...
By Synaffix BV
-
Fluorescence Immunoassay for Detection of Pathogens
Listeriosis is a foodborne infectious disease caused by the pathogen Listeria monocytogenes and is particularly serious for pregnant women and immunocompromised persons. The pathogen is spread mainly through spoiled and contaminated food or animal feed. Methods for the detection of Listeria monocytogenes (LM) on surfaces in the food industry have been developed to control the spread of the ...
-
Confo Therapeutics Enters Collaborative Agreement With Regeneron
Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant conformations, will be ...
-
BOC Sciences Reports Its Antibody Modification and Conjugation Technologies in Detail
The chief technician of BOC Sciences ADC development center recently reported some detailed information regarding its antibody modification and conjugation technologies, bringing the audience and customers a better understanding of how BOC Sciences has contributed to the ADC industry. The newest report on ADC tech released by BOC Sciences officials has attracted much attention from the ...
By BOC Sciences
-
Kyowa Kirin Expands License Agreement with Synaffix and Takes Exclusive Target Rights Based on Latest Positive ADC Data
Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC target Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead program that was built by using Synaffix ADC technology Triggers $5 ...
By Synaffix BV
-
Aclys Bio and Genmab Enter Research and Commercial License Option Agreement
January 26, 2022 – Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated antibody therapeutics for ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you